Archive

Posts Tagged ‘biotech ETFs’

The Biggest Beneficiary Of Biotech’s Comeback

July 10th, 2014

money and investingMichael Robinson: Late last month, I told you that biotech is one of the best ways to profit from the tech rebound. In fact, it was my “No Doz Opportunity No. 1.” Read more…

NASDAQ:BIB, NASDAQ:IBB

The Biotech Bull Market Is Far From Over

July 10th, 2014

biotechThe biotech bull market is not over. That’s the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall. Read more…

NASDAQ:BIB, NASDAQ:IBB

Biotech ETF (IBB) Selling Off On High Volume

July 8th, 2014

sellbuyMorpheus Trading: Monday saw some profit taking in extended industry ETFs, most notably the Biotech ETF (NASDAQ:IBB), which closed -2.6% lower on a pickup in volume. Read more…

NASDAQ:BIB, NASDAQ:IBB

5 Healthcare Micro-Cap Stocks To Watch

July 8th, 2014

healthcare1Jim Bach: A specific group of micro-cap stocks secured a big victory last month, as the Russell Microcap Index boosted its holdings in the sector during its yearly reconstitution. Read more…

NASDAQ:BIB, NASDAQ:IBB

How Will Biotech ETFs Finish Out The Year?

June 18th, 2014

biotechThe Biotechnology ETF world has been on a roller coaster ride this year. After peaking at the beginning of March, the space saw a huge sell-off until the middle of April, after which it has seen some recovery in the past two months. Read more…

NASDAQ:BIB, NASDAQ:IBB, NYSE:PBE, NYSE:XBI

5 Biotech Stocks That Could Double

June 13th, 2014

biotechBillionaires Portfolio: This week the biotech stock Idenix Pharmaceuticals Inc (NASDAQ:IDIX) was acquired by Merck for a 229% premium. That’s one of the biggest one day moves ever, for a stock listed on the New York Stock Exchange. Read more…

NASDAQ:BIB, NASDAQ:IBB

Potential Upside In Canadian Biotech

June 12th, 2014

biotechnologyYou may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling skill sets and pipelines. Read more…

NASDAQ:BIB, NASDAQ:IBB

Making Huge Profits Following Billionaire Investors

June 10th, 2014

money and investingBillionaires Portfolio: Yesterday, Idenix Pharmaceuticals Inc (NASDAQ:IDIX) was acquired by Merck & Co., Inc. (NYSE:MRK) for a 229% premium.  That’s one of the biggest one day moves ever for a stock listed on the New York Stock Exchange.   Read more…

NASDAQ:BIB, NASDAQ:IBB

7 Biotech Stocks To Watch Closely

June 9th, 2014

biotechDiane Alter: A number of promising cancer treatments were presented this week by key global pharmaceutical players at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) – which is why this is a key time of year to watch Read more…

NASDAQ:BIB, NASDAQ:IBB

Cashing In On Biotech

June 5th, 2014

biotechWhen progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestones—which act as catalysts—are met. The Maxim Group’s Senior Managing Director and Head of Healthcare Jason Kolbert Read more…

NASDAQ:BIB, NASDAQ:IBB

Hottest Sector In The Drug Development Industry

May 29th, 2014

drugsWorking in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer’s secrets. The premier event for those in the field is the American Society of Clinical Oncology annual meeting, taking place in Chicago from May 30 to June 1. Read more…

NYSE:XBI

Turn Solid Gold Into Biotech Gold

May 29th, 2014

biotechThe globe-trotting editor and publisher of The Midas Letter has decided to give his metal investments a breather, looking for new prospects in the life sciences space. In this interview with The Life Sciences Report, James West points to low-hanging biofruit ripe for the picking. Read more…

NYSE:XBI

How To Make Money With Generics and Diagnostics

May 22nd, 2014

make-moneyThe concept that generic and specialty pharmaceutical drugs cannot command pricing power and growth is a misunderstanding, according to Director and Senior Analyst Rohit Vanjani of Oppenheimer and Co. Diagnostics also offer upside to investors: Read more…

NASDAQ:BIB, NASDAQ:IBB

Harnessing The Power Of Nature’s Perfect Cells

May 22nd, 2014

biotechNeurosurgeon and serial entrepreneur Robert J. Hariri, founder, chairman and chief science officer at Celgene Cellular Therapeutics, describes how his businesses address some of the great unmet needs in medicine in this interview with The Life Sciences Report. Read more…

NASDAQ:BIB, NASDAQ:IBB

Great Biotech Picks For 2014

May 21st, 2014

biotech2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. Read more…

NASDAQ:BIB, NASDAQ:IBB




Copyright 2009-2014 WBC Media, LLC